Neuroprotective Effects of a Wnt Antagonist in Quinolinic Acid-Induced Excitotoxicity in N18D3 Cells.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture study without human subjects
PubMed 36800814 · doi:10.14715/cmb/2022.68.8.30
What was done
N18D3 neural cell cultures were pretreated with the Wnt5a antagonist Box5 for 1 hour before a 24-hour exposure to quinolinic acid (QUIN), an NMDA receptor agonist. The investigators assessed cell viability and apoptosis using MTT assays and DAPI staining, measured gene expression of pro-apoptotic (BAD, BAX) and anti-apoptotic (Bcl-xL, BCL2, BCLW) targets, and evaluated ERK immunoreactivity.
What was found
Box5 pretreatment protected N18D3 cells from QUIN-induced apoptotic death. Gene expression analysis demonstrated that Box5 prevented the QUIN-induced upregulation of BAD and BAX while increasing expression of Bcl-xL, BCL2, and BCLW. Box5 treatment also significantly increased ERK immunoreactivity. The abstract reports no quantitative values, effect sizes, or p-values.
Why it matters
These findings suggest that inhibiting Wnt5a signaling can attenuate excitotoxicity in neural cells by modulating apoptosis-related gene expression and ERK signaling, highlighting a potential target for neurodegenerative disease models.
Limits
The study is restricted to an in vitro immortalized cell line (N18D3), which lacks the cellular diversity, extracellular environment, and pharmacokinetics of an intact nervous system. The abstract does not provide quantitative data, drug concentrations, sample sizes, or error estimates.
Cited by
- supports Quinolinic acid exerts excitotoxic effects at the NMDA receptor.